Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/22 11:30:30 am
85.93 CHF   +0.37%
01/22NOVARTIS AG : Barclays keeps a Sell rating
MD
01/21NOVARTIS AG : annual earnings release
01/21NOVARTIS AG : Goldman Sachs reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société NOVARTIS AG
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
01/19NOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/14NOVARTIS : Court Rejects Attempt To "Stretch" Patent Claim Language
AQ
01/14NOVARTIS : ligelizumab (QGE031) receives FDA Breakthrough Therapy designation fo..
PU
01/13NOVARTIS : Prosecution History Cannot Be Invoked Against Patent Licensees
AQ
01/11NOVARTIS : Federal Court Clarifies Admissibility Of Prosecution History Evidence..
AQ
2020NOVARTIS : Strict 45-Day Time Limit For Starting PMNOC Action Was Suspended By C..
AQ
2020NOVARTIS : investigational oral therapy iptacopan receives FDA Breakthrough Ther..
AQ
2020NOVARTIS : builds on commitment to addressing need in neuropsychiatric disorders..
PU
2020NOVARTIS : reports positive topline results from second Phase III trial of Beovu..
AQ
2020NOVARTIS : announces positive FDA Advisory Committee recommendation for use of E..
AQ
2020NOVARTIS : investigational oral therapy iptacopan (LNP023) receives FDA Breakthr..
PU
2020NOVARTIS : receives EU approval for Leqvio, a first-in-class siRNA to lower chol..
AQ
2020NOVARTIS : receives EU approval for Leqvio®* (inclisiran), a first-in-class siRN..
PU
2020NOVARTIS : investigational STAMP inhibitor asciminib shows superior MMR rate to ..
AQ
2020NOVARTIS : Kisqali® data demonstrate superior benefit across main intrinsic subt..
PU
2020NOVARTIS : Kisqali® demonstrates nearly five years median overall survival in me..
PU
2020NOVARTIS : investigational STAMP inhibitor asciminib (ABL001) shows superior MMR..
PU
2020NOVARTIS : and Amgen partner with Karamo Brown to support and empower people liv..
AQ
2020NOVARTIS : announces first data from REACH3 trial showing Jakavi® (ruxolitinib) ..
AQ
2020NOVARTIS : Genmab Announces Enapotamab Vedotin Update
AQ
2020NOVARTIS : highlights confidence in growing sales with margin expansion, fueled ..
AQ
2020NOVARTIS : New data at ASH to reinforce breadth of Novartis hematology portfolio..
AQ
2020Pfizer suffers setback in ENBREL battle of patent infringement claim
AQ
2020NOVARTIS : and Enel X present at ANCI 2020 the study on the relationship between..
AQ
2020NOVARTIS : Results from real-world data and post-hoc analysis of Novartis Beovu ..
AQ
2020NOVARTIS : Results from real-world data and post-hoc analysis of Novartis Beovu®..
PU
2020NOVARTIS CASE : Is Rebranding Generic Medicine To The Originator Brand Name Allo..
AQ
2020NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
2020NOVARTIS : Genmab to Present at Jefferies Virtual London Healthcare Conference
AQ
2020MOLECULAR PARTNERS : Novartis provides update on CAN-COVID trial in hospitalized..
AQ
2020Immutep Announces Australian Patent Grant for IMP701 Antibody
AQ
2020NOVARTIS : Cosentyx shows early synovitis reduction in patients with psoriatic a..
AQ
2020NOVARTIS : provides update on CAN-COVID trial in hospitalized patients with COVI..
AQ
2020NOVARTIS : sickle cell medicine Adakveo approved in Europe to prevent recurrent ..
AQ
2020NOVARTIS : acquires Vedere Bio, adding novel optogenetic gene therapy technology..
AQ
2020NOVARTIS : sickle cell medicine Adakveo® approved in Europe to prevent recurrent..
PU
2020MOLECULAR PARTNERS : Novartis announces collaboration with Molecular Partners to..
AQ
2020NOVARTIS : presents latest Phase III data reinforcing Cosentyx® as a first-line ..
PU
2020NOVARTIS : acquires Vedere Bio, adding novel optogenetic gene therapy technology..
PU
2020REGENXBIO : to Receive $80.0 Million Milestone Payment from Novartis AG
AQ
2020NOVARTIS : announces collaboration with Molecular Partners to develop two DARPin..
AQ
2020NOVARTIS : presents promising interim Phase II data of potential first-in-class ..
AQ
2020NOVARTIS : Q3 2020 Results Investor presentation
PU
2020NOVARTIS : 3Q Earnings Snapshot
AQ
2020NOVARTIS : delivers solid Q3 performance with 11% core operating income growth, ..
AQ
2020NOVARTIS : announces European Medicines Agency has granted orphan drug designati..
AQ
2020NOVARTIS : announces European Medicines Agency (EMA) has granted orphan drug des..
PU
2020NOVARTIS : receives US Food and Drug Administration Orphan Drug Designation for ..
AQ
2020NOVARTIS : receives US Food and Drug Administration (FDA) Orphan Drug Designatio..
PU
2020AEQUUS PHARMACEUTICALS : Extends Commercial Agreement for Specialty Product Tacr..
AQ
2020NOVARTIS : Genmab to Host Capital Markets Day
AQ
2020Genmab Announces Data to be presented at SITC 35th Anniversary Annual Meeting
AQ
2020NOVARTIS : received European Medicines Agency PRIME designation for iptacopan in..
AQ
2020NOVARTIS : received European Medicines Agency (EMA) PRIME designation for iptaco..
PU
2020NOVARTIS : Grant of Restricted Stock Units and Warrants to Employees in Genmab
AQ
2020NOVARTIS : New Phase III analysis demonstrates Novartis Beovu showed improvement..
AQ
2020NOVARTIS : New Phase III analysis demonstrates Novartis Beovu® showed improvemen..
PU
2020NOVARTIS : Transactions with shares and linked securities in Genmab A/S made by ..
AQ
2020NOVARTIS : Capital Increase in Genmab as a Result of Employee Warrant Exercise
AQ
2020NOVARTIS : Transactions with shares and linked securities in Genmab A/S made by ..
AQ
2020NOVARTIS : Provides Update on AVXS-101 Intrathecal Clinical Development Program
AQ
2020Here's Why Timber Pharmaceuticals May Be Set to Break Higher; Orphan Drug Foc..
AQ
2020Genmab Commences Binding Arbitration of Two Matters under License Agreement w..
AQ
2020BAUSCH HEALTH : And Alfasigma Announce Resolution Of XIFAXAN Intellectual Proper..
AQ
2020NOVARTIS : Piqray data show survival benefit for patients with HR+/HER2- advance..
AQ
2020Genmab to Present at Morgan Stanley 18th Annual Global Healthcare Conference
AQ
2020NOVARTIS : announces NEJM publication of pivotal study of Tabrecta™ in pat..
PU
2020NOVARTIS : New collaboration between Novartis and Africa Medical Supplies Platfo..
AQ
2020NOVARTIS : New collaboration between Novartis and Africa Medical Supplies Platfo..
AQ
2020NOVARTIS : Genmab Announces Plan to Transition Arzerra to an Oncology Access Pro..
AQ
2020CATALENT : Gene Therapy Facility Receives FDA Approval as an Additional Manufact..
AQ
2020NOVARTIS : receives EC approval for new Xolair® indication to treat severe chron..
PU
2020NOVARTIS : receives Piqray approval in Europe the first and only targeted medici..
AQ
2020NOVARTIS : receives Piqray® approval in Europe – the first and only target..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on NOVARTIS AG